Overall verdict
Neutral
6.0/10
1-year performance
+44.83%
Score breakdown
Up 44.8% over 1 year, 98% of the 52-week range.
Strongest: Profitability 8.8/10. Weakest: Shareholder return 1.6/10.
31 analysts, target +0.0% vs the price.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes ;
Jardiance, Mounjaro, and Trulicity for type 2 diabetes ; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma ; Erbitux for colorectal cancers and head and neck cancers ; Inluriyo for breast cancer ; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma ; Retevmo for the treatment of metastatic NSCLC ;
TYVYT for classic hodgkin's lymphoma ; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F.
Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss ; and Chugai Pharmaceutical Co., Ltd for orforglipron ; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases ; BioArctic AB (publ) for new treatment ; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system ; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Nyse
United States
CEO
David Ricks
Founded
1876
Employees
50 000
Revenue / employee
1.3M USD
Next earnings
February 5, 2027 (estimated)
Institutional holders
- FMR LLC3.18%
- GEODE CAPITAL MANAGEMENT, LLC2.19%
- Bank of New York Mellon Corp0.50%
- Rest of the register94.13%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
1453.00 USD
52-week low
850.51 USD
1-year performance
44.83%
Rising
Year-to-date performance
33.62%
Rising
Drawdown
-1.01%
Near its high
Position in the 52-week range
98% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did better than the world ETF once risk is accounted for.
$10,000 placed at the end of December 2000 are worth today
| Eli Lilly | $303,493 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.7 times as much as the world ETF.
- Worst fall:-61 % between December 2000 and February 2009. $10,000 placed at the top fell to $3,935. The world ETF, at worst: -53 %. Back to its high in 60 months.
Eli Lilly earned 5 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Eli Lilly: $303,493
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 717.64 USD - 720.93 USD (2 methods agree)
The price implies growth of 21.29% per year; the company grows at 25.00%.
Gross margin 83.6%, net margin 31.9%, ROIC 36.3%, ROE 86.1%.
Net margin
31.90%
Exceptional
Sector 9.96%|S&P 13.40%
Gross margin
83.63%
Exceptional
Return on equity (ROE)
86.09%
Exceptional
Sector 6.73%|S&P 17.06%
Return on invested capital (ROIC)
36.31%
Exceptional
Free cash flow margin (FCF)
22.74%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.71x
Fair
Margin stability
10.1 pts
Very uneven
Revenue to net income
Growth
6.1/10Revenue up 38.6% over 1 year, 21.6% a year over 5, EPS 27.6% a year over 5.
Revenue (trailing 12 months)
86.5Md USD
Revenue growth (1y)
38.61%
Hyper-growth
Revenue growth (3y)
128.37%
Hyper-growth
EPS growth (1y)
16.25%
Solid
EPS CAGR (5y)
27.59%
Exceptional
EPS revisions (3 months)
-3.07%
Revised down
Valuation
2.0/10P/E 47.3x, forward P/E 42.1x, EV/EBITDA 29.9x, PEG 1.71. The multiple sits in the 51th percentile of its own 5-year history.
P/E (TTM)
47.3x
Expensive
Sector 27.7x|S&P 23.6x
Forward P/E
42.1x
Very expensive
EV / EBITDA
29.9x
Very expensive
Sector 14.2x|S&P 15.5x
PEG
1.71
Expensive
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
719.29 USD
Deeply overvalued
P/E vs its own 5-year history
among the 49% highest valuations
In line with its history
Market cap
1.4T USD
Financial strength
6.1/10Cash covers 9.9% of the debt, net debt/EBITDA 1.2x.
Net debt / EBITDA
1.2x
Solid
Gearing (net debt / equity)
110.79%
Stretched
Cash
4.9Md USD
Cash / market cap
0.36%
Stretched
Cash / total debt
9.87%
Stretched
Net debt
44.6Md USD
Equity
40.3Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 1,432.29 USD
- MM201,326.71
- MM501,224.51
- MM2001,103.22
- RSI 1469.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.43%
200-day average slope, 3 months
+6.13%
50-day average slope, 1 month
+4.25%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.48 % per day
Volatility change
+23.29%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 34.17 (10) | 35.39 (26) | 91 910 (23) | 43 238 (15) | 30 770 (9) |
| 2027 | 48.00 (12) | 50.64 (28) | 106 485 (29) | 57 456 (17) | 42 697 (11) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 503 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AZN | 7.1 | 7.0 | 286Md USD | 26.7x | 17.7 % | 7.1 % | 14.4 % | 1.2x | 3.6 % | 3.7 % | ||
| 2 | BMY | 6.6 | 6.9 | 129Md USD | 13.9x | 18.5 % | 7.0 % | 14.0 % | 1.9x | 7.2 % | 32.5 % | ||
| 3 | NOVO B | 6.2 | 7.7 | 178Md USD | 10.7x | 33.9 % | 5.6 % | 38.1 % | 0.7x | 6.0 % | -8.5 % | ||
| 4 | ROP | 6.2 | 6.4 | 385Md USD | 26.2x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 4.7 % | 42.5 % | ||
| 5 | NOVN | 6.1 | 6.5 | 295Md USD | 32.0x | 18.0 % | 6.0 % | 13.5 % | 1.0x | 5.0 % | 29.2 % | ||
| 6 | LLY | 6.0 | 5.1 | 1.4T USD | 47.3x | 31.9 % | 38.6 % | 36.3 % | 1.2x | 1.5 % | 44.8 % | ||
| 7 | JNJ | 5.6 | 5.2 | 675Md USD | 42.5x | 16.2 % | 5.9 % | 13.6 % | 0.9x | 3.1 % | 48.1 % | ||
| 8 | MRK | 5.4 | 3.6 | 363Md USD | 150.3x | 3.6 % | 5.5 % | 2.6 % | 1.2x | 4.1 % | 68.5 % | ||
| 9 | PFE | 5.2 | 4.6 | 168Md USD | 42.1x | 6.3 % | -0.4 % | 2.7 % | 2.3x | 7.0 % | 20.3 % |
